USP25 and Alzheimer disease: The genetic deletion or pharmacological inhibition of USP25 was shown to restore microglial homeostasis, curb the release of microglia-driven cytokines and synaptic phagocytosis, diminish Aβ plaque accumulation, and improve synaptic and cognitive functions in AD mouse models (Zheng et al., 2021, 2022).